← All trials
NCT04831086
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 5, 2021
- Primary completion
- Sep 30, 2023
- Completion date
- Dec 30, 2023
- First posted
- Apr 5, 2021
- Last posted
- Jul 19, 2021
- Enrollment
- 340
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BarcelonaLead sponsor
- University of BarcelonaCollaborator
- Universidad Complutense de MadridCollaborator
- University of ValenciaCollaborator
- Autonomous University of MadridCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- University of BarcelonaReponsible party - principal investigator
- Consorci Sanitari de TerrassaCollaborator
- University of BarcelonaCollaborator
- Fundació Recerca Biomèdica ClínicaOverall official - principal investigator
- Hospital Universitario Puerta del MarCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.